Evaluation of Safety and Efficacy of PDP-716

PHASE3CompletedINTERVENTIONAL
Enrollment

682

Participants

Timeline

Start Date

September 13, 2018

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

Brimonidine Tartrate Ophthalmic Suspension

PDP-716

DRUG

Brimonidine Tartrate Ophthalmic Solution

Three Times Brimonidine Tartrate Ophthalmic Solution

Trial Locations (47)

12603

SPARC Site 15, Poughkeepsie

14618

SPARC Site 36, Rochester

16066

SPARC Site 24, Cranberry Township

20715

SPARC Site 40, Bowie

27101

SPARC Site 17, Winston-Salem

27262

SPARC Site 9, High Point

28054

SPARC Site 30, Gastonia

30076

SPARC Site 22, Roswell

30260

SPARC Site 2, Morrow

30349

SPARC Site 42, Atlanta

32204

SPARC Site 21, Jacksonville

33021

SPARC Site 46, Hollywood

33060

SPARC Site 41, Pompano Beach

33064

SPARC Site 29, Deerfield Beach

33067

SPARC Site 11, Coral Springs

33126

SPARC Site 35, Miami

33134

SPARC Site 27, Miami

33143

SPARC Site 10, Miami

33145

SPARC Site 16, Miami

33174

SPARC Site 19, Miami

33175

SPARC Site 25, Miami

33603

SPARC Site 18, Tampa

33901

SPARC Site 34, Fort Myers

38119

SPARC Site 32, Memphis

42001

SPARC Site 23, Paducah

44115

SPARC Site 8, Cleveland

45242

SPARC Site 37, Cincinnati

58103

SPARC Site 33, Fargo

60619

SPARC Site 12, Chicago

63128

SPARC Site 31, St Louis

64055

SPARC Site 28, Kansas City

64133

SPARC Site 48, Kansas City

77008

SPARC Site 39, Houston

78215

SPARC Site 20, San Antonio

78572

SPARC Site 13, Mission

80919

SPARC Site 7, Colorado Springs

85225

SPARC Site 4, Chandler

85351

SPARC Site 3, Sun City

86301

SPARC Site 5, Prescott

90505

SPARC Site 47, Torrance

91204

SPARC Site 44, Glendale

SPARC Site 45, Glendale

91345

SPARC Site 43, Mission Hills

91506

SPARC Site 38, Burbank

92663

SPARC Site 1, Newport Beach

93110

SPARC Site 14, Santa Barbara

05478

SPARC Site 26, Saint Albans

All Listed Sponsors
lead

Sun Pharma Advanced Research Company Limited

INDUSTRY

NCT03450629 - Evaluation of Safety and Efficacy of PDP-716 | Biotech Hunter | Biotech Hunter